Clotrimazole treatment of oral candidiasis in patients with neoplastic disease

Lee B. Shechtman; Laura Funaro; Thomas Robin; Edward J. Bottone; Janet Cuttner

doi:10.1016/0002-9343(84)90755-1

Clotrimazole treatment of oral candidiasis in patients with neoplastic disease

Lee B. Shechtman, Laura Funaro, Thomas Robin, Edward J. Bottone, Janet Cuttner

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

A double-blind controlled study was performed to evaluate the effectiveness of Clotrimazole in the treatment of oral candidiasis in patients with neoplastic disease. Six of seven patients who received clotrimazole had resolution of symptoms and signs of oral candidiasis. In five of six patients who received placebo, clinical progression of signs and symptoms occurred, esophagitis developed, and amphotericin B therapy had to be given. No toxicity was observed that could be attributed to clotrimazole. The results were statistically significant (p = 0.025 by Fisher's exact test). Clotrimazole is effective therapy for oral candidiasis in patients with neoplastic disease, and may prevent the development of esophagitis.

Original language	English
Pages (from-to)	91-94
Number of pages	4
Journal	American Journal of Medicine
Volume	76
Issue number	1
DOIs	https://doi.org/10.1016/0002-9343(84)90755-1
State	Published - Jan 1984

Access to Document

10.1016/0002-9343(84)90755-1

Cite this

@article{5d170dfde9174d889b15638beb31822a,

title = "Clotrimazole treatment of oral candidiasis in patients with neoplastic disease",

abstract = "A double-blind controlled study was performed to evaluate the effectiveness of Clotrimazole in the treatment of oral candidiasis in patients with neoplastic disease. Six of seven patients who received clotrimazole had resolution of symptoms and signs of oral candidiasis. In five of six patients who received placebo, clinical progression of signs and symptoms occurred, esophagitis developed, and amphotericin B therapy had to be given. No toxicity was observed that could be attributed to clotrimazole. The results were statistically significant (p = 0.025 by Fisher's exact test). Clotrimazole is effective therapy for oral candidiasis in patients with neoplastic disease, and may prevent the development of esophagitis.",

author = "Shechtman, {Lee B.} and Laura Funaro and Thomas Robin and Bottone, {Edward J.} and Janet Cuttner",

note = "Funding Information: From the Polly Annenberg Levee Division of Hematology (Department of Medicine) and the Department of Microbiology, Mount Sinai Medical Center, New York, New York. This work was supported in part by Miles Pharmaceuticals and the Alice Rosenzweig Memorial Fund. Requests for reprints should be addressed to Dr. Janet Cuttner, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, New York 10029. Manuscript accepted July 7, 1983. NOTE: Clotrimazole troches have recently become available and are marketed under the name Mycelex troches.",

year = "1984",

month = jan,

doi = "10.1016/0002-9343(84)90755-1",

language = "English",

volume = "76",

pages = "91--94",

journal = "American Journal of Medicine",

issn = "0002-9343",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Clotrimazole treatment of oral candidiasis in patients with neoplastic disease

AU - Shechtman, Lee B.

AU - Funaro, Laura

AU - Robin, Thomas

AU - Bottone, Edward J.

AU - Cuttner, Janet

N1 - Funding Information: From the Polly Annenberg Levee Division of Hematology (Department of Medicine) and the Department of Microbiology, Mount Sinai Medical Center, New York, New York. This work was supported in part by Miles Pharmaceuticals and the Alice Rosenzweig Memorial Fund. Requests for reprints should be addressed to Dr. Janet Cuttner, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, New York 10029. Manuscript accepted July 7, 1983. NOTE: Clotrimazole troches have recently become available and are marketed under the name Mycelex troches.

PY - 1984/1

Y1 - 1984/1

N2 - A double-blind controlled study was performed to evaluate the effectiveness of Clotrimazole in the treatment of oral candidiasis in patients with neoplastic disease. Six of seven patients who received clotrimazole had resolution of symptoms and signs of oral candidiasis. In five of six patients who received placebo, clinical progression of signs and symptoms occurred, esophagitis developed, and amphotericin B therapy had to be given. No toxicity was observed that could be attributed to clotrimazole. The results were statistically significant (p = 0.025 by Fisher's exact test). Clotrimazole is effective therapy for oral candidiasis in patients with neoplastic disease, and may prevent the development of esophagitis.

AB - A double-blind controlled study was performed to evaluate the effectiveness of Clotrimazole in the treatment of oral candidiasis in patients with neoplastic disease. Six of seven patients who received clotrimazole had resolution of symptoms and signs of oral candidiasis. In five of six patients who received placebo, clinical progression of signs and symptoms occurred, esophagitis developed, and amphotericin B therapy had to be given. No toxicity was observed that could be attributed to clotrimazole. The results were statistically significant (p = 0.025 by Fisher's exact test). Clotrimazole is effective therapy for oral candidiasis in patients with neoplastic disease, and may prevent the development of esophagitis.

UR - http://www.scopus.com/inward/record.url?scp=0021364627&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(84)90755-1

DO - 10.1016/0002-9343(84)90755-1

M3 - Article

C2 - 6362409

AN - SCOPUS:0021364627

SN - 0002-9343

VL - 76

SP - 91

EP - 94

JO - American Journal of Medicine

JF - American Journal of Medicine

IS - 1

ER -

Clotrimazole treatment of oral candidiasis in patients with neoplastic disease

Abstract

Access to Document

Fingerprint

Cite this